323 related articles for article (PubMed ID: 36614241)
1. Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma.
Hattinger CM; Salaroglio IC; Fantoni L; Godel M; Casotti C; Kopecka J; Scotlandi K; Ibrahim T; Riganti C; Serra M
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614241
[TBL] [Abstract][Full Text] [Related]
2. An update on emerging drugs in osteosarcoma: towards tailored therapies?
Hattinger CM; Patrizio MP; Magagnoli F; Luppi S; Serra M
Expert Opin Emerg Drugs; 2019 Sep; 24(3):153-171. PubMed ID: 31401903
[No Abstract] [Full Text] [Related]
3. Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies.
Hattinger CM; Patrizio MP; Fantoni L; Casotti C; Riganti C; Serra M
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207685
[TBL] [Abstract][Full Text] [Related]
4. Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies.
Ying H; Li ZQ; Li MP; Liu WC
Front Endocrinol (Lausanne); 2023; 14():1217669. PubMed ID: 37497349
[TBL] [Abstract][Full Text] [Related]
5. Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.
Hattinger CM; Biason P; Iacoboni E; Gagno S; Fanelli M; Tavanti E; Vella S; Ferrari S; Roli A; Roncato R; Giodini L; Scotlandi K; Picci P; Toffoli G; Serra M
Oncotarget; 2016 Sep; 7(38):61970-61987. PubMed ID: 27566557
[TBL] [Abstract][Full Text] [Related]
6. Targeting Clusterin Induces Apoptosis, Reduces Growth Ability and Invasion and Mediates Sensitivity to Chemotherapy in Human Osteosarcoma Cells.
Wang X; Yu Y; Zang L; Zhang P; Ma J; Chen D
Curr Pharm Biotechnol; 2020; 21(2):131-139. PubMed ID: 31433751
[TBL] [Abstract][Full Text] [Related]
7. Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment.
Hattinger CM; Patrizio MP; Luppi S; Magagnoli F; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):299-311. PubMed ID: 30822170
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular recurrence of high-grade osteosarcoma presenting as atrial thrombosis and pulmonary embolism: A case report and review of the pediatric literature.
Ting M; Rodriguez M; Gowda ST; Anders M; Qureshi AM; Grimes A
Pediatr Hematol Oncol; 2019 May; 36(4):244-251. PubMed ID: 31179809
[TBL] [Abstract][Full Text] [Related]
9. Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies.
Liang H; Cui M; Tu J; Chen X
Front Cell Dev Biol; 2024; 12():1394339. PubMed ID: 38915446
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.
Hattinger CM; Vella S; Tavanti E; Fanelli M; Picci P; Serra M
Pharmacogenomics; 2016 Dec; 17(18):2097-2114. PubMed ID: 27883291
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.
Hattinger CM; Tavanti E; Fanelli M; Vella S; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):245-257. PubMed ID: 27758143
[TBL] [Abstract][Full Text] [Related]
12. Drugs in early clinical development for the treatment of osteosarcoma.
Heymann MF; Brown HK; Heymann D
Expert Opin Investig Drugs; 2016 Nov; 25(11):1265-1280. PubMed ID: 27633385
[TBL] [Abstract][Full Text] [Related]
13. Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide.
Byrgazov K; Anderson C; Salzer B; Bozsaky E; Larsson R; Gullbo J; Lehner M; Lehmann F; Slipicevic A; Kager L; Fryknäs M; Taschner-Mandl S
Ther Adv Med Oncol; 2020; 12():1758835920937891. PubMed ID: 32774473
[TBL] [Abstract][Full Text] [Related]
14. Osteosarcoma, personalized medicine, and tissue engineering; an overview of overlapping fields of research.
Bozorgi A; Sabouri L
Cancer Treat Res Commun; 2021; 27():100324. PubMed ID: 33517237
[TBL] [Abstract][Full Text] [Related]
15. The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem.
Corre I; Verrecchia F; Crenn V; Redini F; Trichet V
Cells; 2020 Apr; 9(4):. PubMed ID: 32326444
[TBL] [Abstract][Full Text] [Related]
16. Bone Microenvironment and Osteosarcoma Metastasis.
Yang C; Tian Y; Zhao F; Chen Z; Su P; Li Y; Qian A
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977425
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic strategies for spinal osteosarcomas.
Anwar MA; El-Baba C; Elnaggar MH; Elkholy YO; Mottawea M; Johar D; Al Shehabi TS; Kobeissy F; Moussalem C; Massaad E; Omeis I; Darwiche N; Eid AH
Semin Cancer Biol; 2020 Aug; 64():83-92. PubMed ID: 31152785
[TBL] [Abstract][Full Text] [Related]
18. Focus on Hypoxia-Related Pathways in Pediatric Osteosarcomas and Their Druggability.
Pierrevelcin M; Fuchs Q; Lhermitte B; Messé M; Guérin E; Weingertner N; Martin S; Lelong-Rebel I; Nazon C; Dontenwill M; Entz-Werlé N
Cells; 2020 Aug; 9(9):. PubMed ID: 32878021
[TBL] [Abstract][Full Text] [Related]
19. The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications.
Huang Q; Liang X; Ren T; Huang Y; Zhang H; Yu Y; Chen C; Wang W; Niu J; Lou J; Guo W
Cell Oncol (Dordr); 2021 Jun; 44(3):525-539. PubMed ID: 33788151
[TBL] [Abstract][Full Text] [Related]
20. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma.
Zhang C; Zheng JH; Lin ZH; Lv HY; Ye ZM; Chen YP; Zhang XY
Aging (Albany NY); 2020 Feb; 12(4):3486-3501. PubMed ID: 32039832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
